CalciMedica, Inc. CALC
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-52.48
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$29.6M | — | -$21.2M | -$6.6M |
| 2024 | — | -$13.7M | — | -$21.2M | $14.4M |
| 2023 | — | -$34.4M | — | -$25.8M | $8.2M |
| 2022 | — | -$7.8M | — | -$11.8M | -$71.3M |
| 2021 | — | -$35.8M | — | -$32.0M | -$64.0M |
| 2020 | — | -$27.5M | — | -$33.1M | $94.8M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -52.48 (distress)
- Working capital / assets 0.717
- Retained earnings / assets -13.93
- EBIT / assets -1.701
- Equity / liabilities -0.328
Source: SEC EDGAR filings · CIK 0001534133 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.